首页分享 Ellagic acid (鞣花酸)

Ellagic acid (鞣花酸)

来源：花匠小妙招时间：2024-12-17 18:19

Ellagic acid 是一种天然的抗氧化剂，为有效的，ATP 竞争性的 CK2 和 SHP2 抑制剂，IC50 和 Ki 值分别为 40 nM 和 20 nM。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Ellagic acid Chemical Structure

CAS No. : 476-66-4

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格价格是否有货数量 100 mg ￥266
In-stock 500 mg ￥500
In-stock 1 g ￥700
In-stock 5 g ￥2200
In-stock 10 g 询价 50 g 询价

* Please select Quantity before adding items.

Customer Review

生物活性

Ellagic acid is a natural antioxidant, and acts as a potent and ATP-competitive inhibitor of CK2 and SHP2, with an IC50 of 40 nM and a Ki of 20 nM.

IC50 & Target[1]

CK2

40 nM (IC50)

体外研究
(In Vitro)

Ellagic acid 是一种强效 CK2 抑制剂，IC50 为 40 nM，Ki 为 20 nM，还可阻断其他激酶如 LYN、PKA、SYK、GSK3 等，其 IC50 分别为 2.9、3.5、4.3 和 7.5 μM。Ellagic acid (5-100 μM) 对 Karpas299、SUDHL1、SR786 和 FE-PD 细胞系表现出抑制作用[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Ellagic acid 相关抗体:

BNSP Antibody FACL4 Antibody BrdU Antibody (YA578) GAPDH Antibody Glucose 6 Phosphate Dehydrogenase Antibody METTL3 Antibody TSG101 Antibody Alkaline Phosphatase Antibody Calnexin Antibody (YA573) Catalase Antibody (YA552) Catalase Antibody (YA811) Lamin A/C Antibody Lamin B1 Antibody LAMP1 Antibody LAMP2a Antibody NQO1 Antibody (YA697) NQO1 Antibody (YA261) OPA1 Antibody RBM3 Antibody Synaptophysin Antibody (YA043) Laminin beta 1 Antibody Heme Oxygenase 1 Antibody Ki67 Antibody (YA717) Ki67 Antibody (YA322) Phospho-SHP2 (Tyr542) Antibody Casein Kinase 1 alpha Antibody Casein Kinase 2 beta Antibody Ki67 Antibody (YA001) Synaptophysin Antibody (YA664) TREM2 Antibody 体内研究
(In Vivo)

Ellagic acid (EA；10 mg/kg/天；口服，14 天) 可显著降低大鼠脑中 MDA 含量 17%，并使脑中 TNF-α 水平降低 42%。Ellagic acid 可显著增加 5-HT (39%)、多巴胺 (DA，71%) 和去甲肾上腺素 (NE，77%) 的脑含量。Ellagic acid (10 mg/kg，口服，14 天) 可减轻大鼠中阿霉素引起的组织病理学变化[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial NCT NumberSponsorConditionStart DatePhaseNCT02263378University of Messina

HPV Infection

September 2014Not ApplicableNCT03713164University of California, Los Angeles

Healthy

February 22, 2018Not ApplicableNCT00455416Oslo University Hospital|University of Oslo

Follicular Lymphoma

April 2007Phase 2 NCT04011618University of Guadalajara|National Council of Science and Technology, Mexico

Metabolic Syndrome

September 17, 2019Phase 2 分子量

302.19

Formula

C14H6O8

CAS 号

476-66-4

性状

固体

颜色

Light yellow to khaki

中文名称

鞣花酸

结构分类 Phenols Polyphenols 初始来源植物其他科微生物内源性代谢物运输条件

Room temperature in continental US; may vary elsewhere.

储存方式 Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months 溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 2.5 mg/mL (8.27 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量 1 mg 5 mg 10 mg 1 mM 3.3092 mL 16.5459 mL 33.0918 mL 5 mM 0.6618 mL 3.3092 mL 6.6184 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

摩尔计算器

稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量

浓度

体积

分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

体积 (start)

浓度 (final)

体积 (final)

动物实验：

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： 50% PEG300 50% Saline

Solubility: 40 mg/mL (132.37 mM); 悬浊液; 超声助溶

扫码获得
动物溶解方案

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

纯度 & 产品资料

纯度： 99.23%

选择批次：

Data Sheet (643 KB) SDS (392 KB)

COA (296 KB)HNMR (243 KB)RP-HPLC (253 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Cozza G, et al. Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. J Med Chem. 2006 Apr 20;49(8):2363-6. [Content Brief]

[2]. Rizk HA, et al. Prophylactic effects of ellagic acid and rosmarinic acid on doxorubicin-induced neurotoxicity in rats. J Biochem Mol Toxicol. 2017 Dec;31(12). [Content Brief]

[3]. Ahire V, et al. Ellagic Acid Enhances Apoptotic Sensitivity of Breast Cancer Cells to γ-Radiation. Nutr Cancer. 2017 Aug-Sep;69(6):904-910. [Content Brief]

[4]. Ma CH, et al. Discovery of ellagic acid as a competitive inhibitor of Src homology phosphotyrosyl phosphatase 2 (SHP2) for cancer treatment: In vitro and in silico study. Int J Biol Macromol. 2023 Nov 5;254(Pt 2):127845. [Content Brief]

Kinase Assay
[1]

CK2 and CK1 phosphorylation assays are carried out at 37°C in the presence of increasing amounts of each inhibitor (Ellagic acid) in a final volume of 25 µL containing 50 mM, Tris-HCl pH 7.5, 100 mM NaCl, 12 mM MgCl2, 0.02 mM [33P-ATP] (500-1000 cpm/pmol), unless otherwise indicated. The phosphorylatable substrates are the synthetic peptide substrate RRRADDSDDDDD (100 µM) and RRKHAAIGDDDDAYSITA (200 µM) for CK2 and CK1, respectively. Reaction started with the addition of the kinase and is stopped after 10 min. by addition of 5 µL of 0.5 M orthophosphoric acid before spotting aliquots onto phosphocellulose filters. Filters are washed in 75 mM phosphoric acid substrate following SDS-PAGE of the radiolabeled samples. DYRK1A, assayed on the peptide RRRFRPASPLRGPPK, and tyrosine kinase activities are determined[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay
[1]

ALCL cell viability is measured by MTT assay. Briefly, 0.1 × 105 cells are seeded onto 96-well microculture plates 12 hrs before adding ellagic acid. The cells are grown in 200 µL of complete RPMI-1640 medium, under standard tissue-culture conditions, in the presence or absence of the drug (Ellagic acid) for 48 hours. Twenty µL of MTT solution (5 mg/mL) are then added to the cell suspension for 4h. The intracellular formazan crystals are dissolved with 150 µL of DMSO and optical density, measured on a spectrophotometer at 540 nm, represents the mean (± SD) of triplicate cultures[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[2]

Fifty male adult Sprague-Dawley rats are divided randomly into five groups as follow: Group (1) receives corn oil orally as a vehicle and served as normal control. Group (2) receives doxorubicin (DOX) injection (5 mg/kg, i.p.) twice a week for 14 days. Group (3) receives Ellagic acid (10 mg/kg, p.o.; daily) for 14 days and DOX (5 mg/kg, i.p.) twice a week for 14 days. Group (4) receives rosmarinic acid (RA; 75 mg/kg, p.o.; daily) for 14 days and DOX (5 mg/kg, i.p.) twice a week for 14 days. Group (5) receives Ellagic acid (10 mg/kg, p.o.; daily) with RA (75 mg/kg, p.o.; daily) for 14 days and DOX injection (5 mg/kg, i.p.) twice a week for 14 days[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[2]. Rizk HA, et al. Prophylactic effects of ellagic acid and rosmarinic acid on doxorubicin-induced neurotoxicity in rats. J Biochem Mol Toxicol. 2017 Dec;31(12). [Content Brief]

[3]. Ahire V, et al. Ellagic Acid Enhances Apoptotic Sensitivity of Breast Cancer Cells to γ-Radiation. Nutr Cancer. 2017 Aug-Sep;69(6):904-910. [Content Brief]

[1]. Cozza G, et al. Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. J Med Chem. 2006 Apr 20;49(8):2363-6.

[2]. Rizk HA, et al. Prophylactic effects of ellagic acid and rosmarinic acid on doxorubicin-induced neurotoxicity in rats. J Biochem Mol Toxicol. 2017 Dec;31(12).

[3]. Ahire V, et al. Ellagic Acid Enhances Apoptotic Sensitivity of Breast Cancer Cells to γ-Radiation. Nutr Cancer. 2017 Aug-Sep;69(6):904-910.

Ellagic acid 相关分类

天然产物疾病研究领域植物酚类微生物内源性代谢物癌症神经系统疾病抗衰老其他科多酚类 Neurological Disease Cancer 肿瘤靶向治疗肿瘤免疫肿瘤干细胞肿瘤代谢与转移 Cell Cycle/DNA Damage Stem Cell/Wnt Immunology/Inflammation NF-κB Metabolic Enzyme/Protease Protein Tyrosine Kinase/RTK Casein Kinase Reactive Oxygen Species Endogenous Metabolite SHP2